Sebastiaan Engelborghs
#150,443
Most Influential Person Now
Researcher
Sebastiaan Engelborghs's AcademicInfluence.com Rankings
Sebastiaan Engelborghscomputer-science Degrees
Computer Science
#7878
World Rank
#8292
Historical Rank
Artificial Intelligence
#3371
World Rank
#3420
Historical Rank
Database
#4937
World Rank
#5130
Historical Rank
Download Badge
Computer Science
Sebastiaan Engelborghs's Degrees
- PhD Computer Science University of Amsterdam
- Masters Artificial Intelligence University of Amsterdam
- Bachelors Computer Science University of Amsterdam
Similar Degrees You Can Earn
Why Is Sebastiaan Engelborghs Influential?
(Suggest an Edit or Addition)Sebastiaan Engelborghs's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
- Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease (2011) (1701)
- Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease (2009) (1644)
- Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease (2009) (1476)
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes (2009) (1441)
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2013) (1388)
- Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 (2006) (1377)
- Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
- Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
- A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study (2012) (630)
- TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis (2014) (580)
- APOE and Alzheimer disease: a major gene with semi-dominant inheritance (2011) (528)
- Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. (2010) (446)
- A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
- sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers (2016) (341)
- The Lateralized Linguistic Cerebellum: A Review and a New Hypothesis (2001) (321)
- A Practical Guide to Immunoassay Method Validation (2015) (320)
- Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology (2013) (308)
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2012) (295)
- Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. (2012) (291)
- Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. (2015) (285)
- Monitoring of physical activity after stroke: a systematic review of accelerometry-based measures. (2010) (269)
- A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats (2012) (254)
- New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) (246)
- The genetics and neuropathology of frontotemporal lobar degeneration (2012) (244)
- Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia (2008) (240)
- FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration (2010) (230)
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
- Genetic contribution of FUS to frontotemporal lobar degeneration (2010) (204)
- Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study (2018) (204)
- Serum biomarker for progranulin‐associated frontotemporal lobar degeneration (2009) (200)
- Consensus guidelines for lumbar puncture in patients with neurological diseases (2017) (197)
- The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter (2015) (194)
- Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites (2011) (191)
- Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. (2006) (186)
- The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative (2014) (174)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study (2016) (170)
- Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia (2014) (165)
- Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease (2012) (163)
- Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis (2014) (163)
- High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. (2005) (154)
- Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease (2008) (149)
- CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. (2008) (147)
- Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort (2015) (146)
- Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P (2009) (144)
- The Vascular Impairment of Cognition Classification Consensus Study (2017) (140)
- Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. (2007) (137)
- Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease (2008) (137)
- Pathophysiology of epilepsy. (2000) (135)
- Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? (2009) (123)
- Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects (2003) (123)
- Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia (2017) (121)
- Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia (2007) (121)
- Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study (2015) (120)
- TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions (2014) (119)
- Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease (2008) (116)
- Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
- TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort (2011) (114)
- Neuropsychiatric symptoms of dementia: cross‐sectional analysis from a prospective, longitudinal Belgian study (2005) (113)
- No association of CSF biomarkers with APOEε4, plaque and tangle burden in definite Alzheimer's disease (2007) (113)
- C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease (2015) (112)
- Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. (2014) (112)
- Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. (2015) (106)
- Serum N-glycan profile shift during human ageing (2010) (105)
- Inflammatory biomarkers in Alzheimer's disease plasma (2019) (104)
- Cognitive, linguistic and affective disturbances following a right superior cerebellar artery infarction: A case study (2009) (103)
- Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment (2017) (100)
- Cognitive, affective and behavioural disturbances following vascular thalamic lesions: A review (2011) (99)
- Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. (2011) (97)
- Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia (2017) (94)
- SORL1 is genetically associated with increased risk for late‐onset Alzheimer disease in the Belgian population (2008) (94)
- Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration (2014) (93)
- Progranulin locus deletion in frontotemporal dementia (2008) (93)
- Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review (2019) (91)
- A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42 (2015) (90)
- Risk Factors for Poststroke Depression (2014) (90)
- Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. (2006) (90)
- Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS (2009) (90)
- Biobanking of CSF: international standardization to optimize biomarker development. (2014) (90)
- Pathophysiology of language switching and mixing in an early bilingual child with subcortical aphasia (2005) (89)
- Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. (2015) (88)
- Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His (2009) (88)
- Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. (2013) (86)
- Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2021) (85)
- A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. (2006) (85)
- Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study. (2013) (85)
- TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2017) (85)
- Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances (2004) (83)
- Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging (2019) (82)
- Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk (2012) (81)
- The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease (2005) (80)
- Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort (2015) (78)
- A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease (2016) (77)
- Loss of psychic self-activation after paramedian bithalamic infarction. (2000) (76)
- A role for the cerebellum in motor speech planning: Evidence from foreign accent syndrome (2006) (76)
- Long-term cognitive deficits following posterior fossa tumor resection: a neuropsychological and functional neuroimaging follow-up study. (2009) (74)
- Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum (2019) (74)
- DLB and PDD: a role for mutations in dementia and Parkinson disease genes? (2012) (74)
- A Prospective Study on the Prevalence and Risk Factors of Poststroke Depression (2013) (73)
- Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. (2013) (72)
- The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia (2008) (72)
- Amino Acids and Biogenic Amines in Cerebrospinal Fluid of Patients with Parkinson's Disease (2003) (72)
- Poststroke depression and its multifactorial nature: Results from a prospective longitudinal study (2014) (72)
- Alzheimer’s disease CSF biomarkers: clinical indications and rational use (2017) (71)
- Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population (2009) (71)
- Aphasia following cerebellar damage: fact or fallacy? (2000) (70)
- Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels (2014) (70)
- Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease (2014) (69)
- No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. (2007) (68)
- Added diagnostic value of CSF biomarkers in differential dementia diagnosis (2010) (67)
- Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type (1999) (67)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (66)
- New insights on the genetic etiology of Alzheimer’s and related dementia (2020) (64)
- Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. (2015) (64)
- Erratum: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (2009) (64)
- Identification of 2 Loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2010) (63)
- Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke (2017) (63)
- Differentiation between mild cognitive impairment, Alzheimer's disease and depression by means of cued recall (2005) (62)
- The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes (2011) (61)
- C9orf72 G4C2 repeat expansions in Alzheimer's disease and mild cognitive impairment (2013) (60)
- The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting (2017) (60)
- Dose dependent effect of APOE ɛ4 on behavioral symptoms in frontal lobe dementia (2006) (60)
- Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. (2015) (60)
- Actigraphic measurement of agitated behaviour in dementia (2006) (59)
- Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer's disease (2013) (59)
- Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients (2017) (58)
- Clinical Evidence of Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion (2017) (58)
- Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis (2018) (58)
- A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. (2007) (58)
- A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort (2019) (57)
- Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease (2014) (57)
- Neuropsychological and behavioural correlates of CSF biomarkers in dementia (2006) (57)
- Genotype–phenotype links in frontotemporal lobar degeneration (2018) (57)
- An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease (2018) (56)
- The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. (2010) (55)
- Actigraphic Measurement of Motor Deficits in Acute Ischemic Stroke (2008) (54)
- Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (53)
- Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults (2013) (53)
- Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study (2018) (53)
- Association study of cholesterol-related genes in Alzheimer’s disease (2007) (53)
- The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. (2013) (53)
- Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer’s disease (2017) (53)
- No correlation between time-linked plasma and CSF Aβ levels (2009) (52)
- Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
- APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease (2009) (52)
- Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment (2009) (52)
- Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer's disease. (2014) (52)
- Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients (2008) (51)
- No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration (2011) (51)
- Phonological agraphia following a focal anterior insulo-opercular infarction (2001) (51)
- How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio (2017) (50)
- A Foreign Speech Accent in a Case of Conversion Disorder (2006) (49)
- The many faces of crossed aphasia in dextrals: report of nine cases and review of the literature (2001) (49)
- The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease (2016) (49)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (48)
- Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics (2019) (48)
- Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor (2016) (47)
- Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. (2015) (46)
- Volumetric evaluation of upper extremities in 250 healthy persons (2007) (46)
- Cerebellar-induced apraxic agraphia: A review and three new cases (2011) (46)
- Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies. (2013) (45)
- Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis (2015) (45)
- Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia (2004) (45)
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
- Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts (2012) (44)
- Functional anatomy, vascularisation and pathology of the human thalamus. (1998) (44)
- The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease (2015) (44)
- Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis? (2015) (44)
- Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. (2012) (44)
- Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations (2015) (44)
- Prediction of Upper Limb Recovery, General Disability, and Rehabilitation Status by Activity Measurements Assessed by Accelerometers or the Fugl-Meyer Score in Acute Stroke (2014) (42)
- Mutated ATP10B increases Parkinson’s disease risk by compromising lysosomal glucosylceramide export (2020) (40)
- Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration (2018) (40)
- Identifying frailty risk profiles of home-dwelling older people: focus on sociodemographic and socioeconomic characteristics (2017) (40)
- Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients (2013) (40)
- Detecting frail, older adults and identifying their strengths: results of a mixed-methods study (2018) (40)
- Foreign accent syndrome as a developmental motor speech disorder (2009) (40)
- Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia (2013) (39)
- Common variation in GRB‐associated Binding Protein 2 (GAB2) and increased risk for Alzheimer dementia (2009) (39)
- Rationale and clinical data supporting nutritional intervention in Alzheimer’s disease (2014) (39)
- The neurochemistry of Alzheimer's disease. (1997) (38)
- A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. (2016) (38)
- Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models (2005) (38)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (38)
- Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study (2015) (37)
- Promoter DNA methylation regulates progranulin expression and is altered in FTLD (2013) (37)
- Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimer’s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression (2016) (36)
- Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. (2018) (36)
- Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
- Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study (2020) (36)
- Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. (2006) (36)
- Alzheimers disease biomarkers: from concept to clinical utility (2008) (36)
- Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. (2013) (35)
- Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. (2016) (35)
- Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay (2019) (35)
- Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team (2016) (35)
- Follow-up study of susceptibility loci for Alzheimer's disease and onset age identified by genome-wide association. (2010) (34)
- TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (34)
- Cerebellar cognitive affective syndrome without global mental retardation in two relatives with Gillespie syndrome (2008) (34)
- Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review (2020) (33)
- Mild Cognitive Impairment: What’s in a Name? (2006) (33)
- Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study (2015) (32)
- Cerebellar neurocognition: a new avenue. (2001) (32)
- Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer disease and highlights potential translational opportunities (2020) (32)
- BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants (2017) (31)
- SolCos model-based individual reminiscence for older adults with mild to moderate dementia in nursing homes: a randomized controlled intervention study. (2016) (31)
- Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability (2019) (31)
- Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls. (2014) (31)
- Psychosocial problems associated with depression at 18 months poststroke (2014) (31)
- Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function (2017) (31)
- Altered serum glycomics in Alzheimer disease: a potential blood biomarker? (2010) (31)
- Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia (2015) (31)
- Typing competencies in Alzheimer's disease: An exploration of copy tasks (2017) (30)
- Behavioral syndromes in mild cognitive impairment and Alzheimer's disease. (2013) (30)
- Behavioural and neuropsychological correlates of frontal lobe features in dementia (2006) (30)
- NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients (2018) (29)
- Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset (2019) (28)
- No association between CALHM1 and risk for Alzheimer dementia in a Belgian population (2009) (28)
- Encephalitis associated with the SARS-CoV-2 virus: A case report (2020) (28)
- Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis (2014) (28)
- The UBQLN1 polymorphism, UBQ-8i, at 9q22 is not associated with Alzheimer's disease with onset before 70 years (2006) (28)
- Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. (2010) (28)
- Crossed Aphasia and Visuo-Spatial Neglect Following a Right Thalamic Stroke: A Case Study and Review of the Literature (2008) (27)
- 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against 15O-H2O PET (2019) (27)
- CFAI‐Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument (2018) (26)
- Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
- Melatonin levels in the Alzheimer’s disease continuum: a systematic review (2021) (26)
- The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study (2017) (25)
- Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson’s disease and increase susceptibility to dementia in a Flanders-Belgian cohort (2016) (25)
- Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study (2020) (25)
- Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation (2016) (24)
- Impairment of syntax and lexical semantics in a patient with bilateral paramedian thalamic infarction (2006) (24)
- Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population (2012) (24)
- Progranulin variability has no major role in Parkinson disease genetic etiology (2008) (24)
- The frequency and influence of dementia risk factors in prodromal Alzheimer's disease (2017) (24)
- Clinical indications for analysis of Alzheimer's disease CSF biomarkers. (2013) (23)
- Contribution of TARDBP to Alzheimer's disease genetic etiology. (2010) (23)
- Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis (2018) (23)
- GIGYF2 has no major role in Parkinson genetic etiology in a Belgian population (2011) (23)
- Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. (2016) (23)
- Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer’s Disease (2016) (23)
- Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard. (2013) (22)
- Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer's disease and related endophenotypes (2013) (22)
- Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories (2010) (22)
- Rare Variants in PLD3 Do Not Affect Risk for Early‐Onset Alzheimer Disease in a European Consortium Cohort (2015) (22)
- The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer’s Disease (2012) (22)
- Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease (2019) (21)
- The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications (2019) (21)
- Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm (2020) (21)
- C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (2015) (20)
- Techniques, Contraindications, and Complications of CSF Collection Procedures (2015) (20)
- Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia (2018) (20)
- Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia (2015) (20)
- Predictive value of upper-limb accelerometry in acute stroke with hemiparesis. (2013) (19)
- Tau Monoclonal Antibody Generation Based on Humanized Yeast Models (2014) (19)
- Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases (2016) (19)
- Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. (2016) (19)
- Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and FTD (2016) (19)
- TBK 1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2019) (18)
- The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: A pilot study (2013) (18)
- Crossed cerebellar diaschisis and hemiataxia after thalamic hemorrhage (2000) (18)
- Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis (2018) (18)
- Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity (2017) (17)
- Comprehensive genetic and mutation analysis of familial dementia with Lewy bodies linked to 2q35-q36. (2010) (17)
- Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey (2020) (17)
- A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer’s Disease (REMEMBER) (2018) (17)
- Differentiation Between Dementia and Depression Among Older Persons: Can the Difference Between Actual and Premorbid Intelligence Be Useful? (2008) (17)
- Exploring Cognitive Frailty: Prevalence and Associations with Other Frailty Domains in Older People with Different Degrees of Cognitive Impairment (2019) (17)
- LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. (2007) (16)
- Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson’s disease (2021) (16)
- Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC) (2019) (16)
- Clinical variability and onset age modifiers in an extended Belgian GRN founder family (2018) (16)
- Souvenaid in the management of mild cognitive impairment: an expert consensus opinion (2019) (16)
- Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains (2015) (15)
- EEG Dominant Frequency Peak Differentiates Between Alzheimer’s Disease and Frontotemporal Lobar Degeneration (2016) (15)
- The 10-word learning task in the differential diagnosis of early Alzheimer's disease and elderly depression: A cross-sectional pilot study (2011) (15)
- Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort (2018) (15)
- Correlation between actigraphy and nurses' observation of activity in dementia (2007) (14)
- Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update (2012) (14)
- Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort (2020) (14)
- A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer’s disease (2017) (14)
- No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis (2017) (13)
- No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients (2018) (13)
- Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. (1998) (13)
- Guanosine triphosphate cyclohydrolase 1 promoter deletion causes dopa‐responsive dystonia (2012) (13)
- The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia (2012) (13)
- Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations (2020) (12)
- DNMBP is genetically associated with Alzheimer dementia in the Belgian population (2009) (12)
- Acquired Crossed Aphasia in Dextral Children Revisited (2001) (12)
- Randomized controlled trial to evaluate a prevention program for frail community-dwelling older adults: a D-SCOPE protocol (2018) (12)
- Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. (2019) (12)
- European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment (2020) (12)
- Headache As Only Symptom in Multiple Cervical Artery Dissection (2001) (12)
- Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors (2016) (12)
- Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. (2003) (11)
- Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. (2017) (11)
- Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort (2018) (11)
- Callosal circularity as an early marker for Alzheimer's disease (2018) (11)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (11)
- Prolyl Carboxypeptidase Activity Decline Correlates with Severity and Short-Term Outcome in Acute Ischemic Stroke (2014) (11)
- Limited engagement in, yet clear preferences for advance care planning in young-onset dementia: An exploratory interview-study with family caregivers (2019) (11)
- Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios (2022) (10)
- Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers (2022) (10)
- Multicenter Analytical Validation of Aβ40 Immunoassays (2017) (10)
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (vol 41, pg 1088, 2009) (2013) (10)
- Impact of hearing loss and vestibular decline on cognition in Alzheimer’s disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECkO) (2020) (10)
- Characteristics of subjective cognitive decline associated with amyloid positivity (2021) (10)
- Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey (2015) (9)
- Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits (2021) (9)
- Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family (2018) (9)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels (2021) (9)
- Cognitive and linguistic disturbances in the posterior fossa syndrome in children: a diaschisis phenomenon? (2003) (9)
- Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview (2021) (9)
- [Apathy, depression and cognitive functioning in patients with MCI and dementia]. (2018) (9)
- FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration (2010) (8)
- Replication study of plasma proteins relating to Alzheimer's pathology (2021) (8)
- Alzheimer’s disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association (2017) (8)
- Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients (2021) (8)
- Reversal of head drop after discontinuation of olanzapine in a DLB patient (2008) (8)
- Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects (2019) (8)
- CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports (2021) (8)
- Pre-analytical stability of novel cerebrospinal fluid biomarkers. (2019) (8)
- Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies (2021) (8)
- FMRI findings in an aphasic patient with reversed cerebral dominance for language. (2008) (8)
- Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort (2021) (7)
- Anomalous Cerebral Language Organization: Acquired Crossed Aphasia in a Dextral Child (2001) (7)
- Next Generation Brain Health Depends on Early Alzheimer Disease Diagnosis: From a Timely Diagnosis to Future Population Screening. (2016) (7)
- Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia (2021) (7)
- Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus (2021) (7)
- Are depressive symptoms in mild cognitive impairment predictive of conversion to dementia? (2016) (6)
- The value of cerebrospinal fluid biomarkers for the differential diagnosis of dementia (2012) (6)
- Comparing Advance Care Planning in Young-Onset Dementia in the USA vs Belgium: Challenges Partly Related to Societal Context. (2020) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation (2022) (6)
- A Systematic Review of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Methodological Considerations (2021) (6)
- Mastication Dyspraxia: A Neurodevelopmental Disorder Reflecting Disruption of the Cerebellocerebral Network Involved in Planned Actions (2013) (6)
- Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer’s Disease and Controls (2021) (6)
- CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives (2013) (5)
- Severe bilateral subdural hematomas as a complication of diagnostic lumbar puncture for possible Alzheimer’s disease (2017) (5)
- Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study (2015) (5)
- Disrupted Auto-Activation, Dysexecutive and Confabulating Syndrome Following Bilateral Thalamic and Right Putaminal Stroke (2008) (5)
- A qualitative study with people with young-onset dementia and their family caregivers on advance care planning: A holistic, flexible, and relational approach is recommended (2022) (5)
- Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer’s Disease in a Clinical Setting: A REMEMBER Study (2021) (5)
- Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review (2021) (5)
- PHARMACODYNAMICS OF THE ORAL BACE INHIBITOR JNJ-54861911 IN EARLY ALZHEIMER'S DISEASE (2016) (5)
- Incidence of upper limb oedema in patients with acute hemiparetic stroke (2011) (5)
- Is activity loss predictive for development of upper limb oedema after stroke? (2011) (5)
- TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer’s disease biomarker levels (2020) (5)
- Brain-specific tryptophan hydroxylase, TPH2, and 5-HTTLPR are associated with frontal lobe symptoms in Alzheimer's disease. (2013) (5)
- A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort (2019) (4)
- CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER’S DISEASE: AN ASSAY COMPARISON STUDY (2017) (4)
- Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer’s disease (2020) (4)
- Loss-of-function mutations in TBK1 are frequently associated with frontotemporal lobar degeneration in a belgian patient cohort (2015) (4)
- Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset (2022) (4)
- Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing Status (2022) (4)
- Recommendations for the treatment of epilepsies in general practice in Belgium. (2008) (4)
- Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology (2020) (3)
- Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions (2015) (3)
- A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms (2020) (3)
- Melatonin levels in the Alzheimer’s disease continuum: a systematic review (2021) (3)
- Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. (2021) (3)
- Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia (2017) (3)
- Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity (2022) (3)
- Case report of a patient with complex partial frontal lobe seizures as a complication of bifrontal lobotomy. (1998) (3)
- CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals (2021) (3)
- P1-321 Contribution of dementia genes to Alzheimer’s disease in Belgium (2006) (3)
- Stronger Correlations between Neurophysiological and Peripheral Disease Biomarkers Predict Better Prognosis in Two Severe Diseases (2019) (3)
- Overdiagnosis of vascular dementia using structural brain imaging in the context of standard clinical diagnostic criteria (2011) (3)
- Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease (2022) (2)
- P3-392: The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia (2008) (2)
- No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers (2020) (2)
- Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease (2021) (2)
- 5‐HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease (2004) (2)
- O3-05-01 A novel presenilin 1 mutation (gly183val) is associated with pick's disease in the absence of β-amyloid plaques (2004) (2)
- EARLY FRAME 18F-AV45 AND 18F-FDG-PET AS PROXIES OF CBF: COMPARISON TO 15O-H2O PET DATA (2017) (2)
- Apraxic agraphia following thalamic damage: Three new cases (2015) (2)
- Serum Glutamine Synthetase Has No Value as a Diagnostic Biomarker for Alzheimer’s Disease (2011) (2)
- P1-425 Behavioral and neuropsychological correlates of frontal lobe features in dementia (2006) (2)
- Influence of AD pathology on CSF biomarkers in autopsy-confirmed Dementia With Lewy Bodies patients (2011) (2)
- Clinical Features of TBK1 Carriers and Comparison with C9orf72, GRN and Nonmutation Carriers in a Belgian Patient Cohort (S21.007) (2016) (2)
- Risk For Alzheimer's Associated With A Copy Number Variation In The Complement Receptor 1 Increasing C3b/C4b Binding Sites (2011) (2)
- Admetrix: A new method for atrophy quantification in Alzheimer's disease (2015) (2)
- Practices and opinions about disclosure of the diagnosis of Alzheimer’s disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia (2020) (1)
- A monoclonal antibody-based elisa for neurogranin (2015) (1)
- THE MONTREAL COGNITIVE ASSESSMENT INSTRUMENT: INFLUENCE OF DEPRESSIVE SYMPTOMS (2014) (1)
- Rare variants in IFFO1, DTNB and NLRC3 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation (2021) (1)
- Behavioral symptoms in mild cognitive impairment as compared to Alzheimer's disease and healthy elderly (2011) (1)
- Crossed Aphasia in Children (2004) (1)
- Cognitive Writing Process Characteristics in Alzheimer’s Disease (2022) (1)
- Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks (2022) (1)
- Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk (2012) (1)
- NEUROGRANIN IN CEREBROSPINAL FLUID IS NOT SPECIFIC TO ALZHEIMER’S DISEASE DEMENTIA (2018) (1)
- Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review (2019) (1)
- THE MAPT P.ARG406TRP IS A FOUNDER MUTATION IN BELGIUM AND PRESENTS WITH AN ALZHEIMER DISEASE DEMENTIA-LIKE PHENOTYPE (2017) (1)
- Predicting conversion to Alzheimer's disease in Mild Cognitive Impairment: cued recall versus free delayed recall (2010) (1)
- 3xTg Alzheimer’s disease mice are more susceptible to induced seizures (2020) (1)
- Featured Article Profiling the dynamics of CSF and plasma Ab reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor (2016) (1)
- A DECADE OF CEREBROSPINAL FLUID BIOMARKERS FOR ALZHEIMER’S DISEASE IN BELGIUM (2016) (1)
- P1-344: Plasma amyloid isoforms in non-Alzheimer's disease patients (2008) (1)
- EEG DOMINANT FREQUENCY PEAK DIFFERENTIATES BETWEEN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION (2016) (1)
- Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease (2011) (1)
- International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease (2020) (1)
- Biomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study (2022) (1)
- GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (1)
- EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER’S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY (2017) (1)
- Souvenaid in the management of mild cognitive impairment: an expert consensus opinion (2019) (1)
- DIAGNOSTIC ACCURACY OF CSF AMYLOID-B ISOFORMS FOR EARLY AND DIFFERENTIAL DEMENTIA DIAGNOSIS (2014) (1)
- MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study (2018) (1)
- P1-166: CSF biomarkers predict conversion to dementia in mild cognitive impairment (2008) (1)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER’S DISEASE PROGRESSION (2018) (1)
- Detection and quantification of novel tau/phospho-tau epitopes in CSF using a multiplex assay approach (2013) (1)
- COMBINATION OF CEREBROSPINAL FLUID H-FABP AND CORE ALZHEIMER'S DISEASE BIOMARKERS IMPROVES THE DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISORDERS (2016) (1)
- Resting state functional MRI as a possible biomarker for Alzheimer’s disease: An innovative approach for robust extraction of the default mode network (2015) (1)
- VALIDATION OF THE AD-CSF INDEX IN AUTOPSY CONFIRMED AD PATIENTS AND HEALTHY CONTROLS (2014) (1)
- [Early diagnosis of Alzheimer's disease (with the announcement of the diagnosis)]. (2020) (1)
- HIGH SCORES ON A 22-GENE RISK SCORE FOR ALZHEIMER'S DEMENTIA CORRELATE WITH EARLIER ONSET AGE AND REDUCED CSF Aβ (2014) (1)
- VOLUMETRIC BRAIN MRI OF DIFFERENT REGIONS, INCLUDING THE HIPPOCAMPUS, IN THE ALZHEIMER’S DISEASE SPECTRUM: A SYSTEMATIC REVIEW (2016) (1)
- Familial sinistrality in crossed aphasia: A new case and review of the available literature (2001) (1)
- Development of novel elisas for the quantification of both pan-ApoE and ApoE4 proteins in CSF and blood, and ApoE ε4 phenotyping (2015) (1)
- LONGITUDINAL COMPARISON OF CSF BIOMARKERS OF NEURODEGENERATION IN PATIENTS WITH PROBABLE IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH) (2019) (1)
- Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer’s Disease but Are Not Correlated with Cognitive Decline (2021) (1)
- O2-07-02: Is the geriatric depression scale a reliable screening tool for depressive symptoms in elderly patients with cognitive impairment? (2008) (1)
- Executive functions in primary progressive aphasia: A meta-analysis (2022) (1)
- P3-068: Improved discrimination of Alzheimer's disease from other dementias using cerebrospinal fluid P-tau181P (2008) (1)
- P3-202: The neuronal sorting receptor SORL1 is genetically associated with increased risk for late-onset Alzheimer's disease in the Belgian population (2008) (1)
- P3-159 MAPT H1 subhaplotyping in european PD association samples implicates tau splicing in early-onset parkinson’s disease susceptibility (2006) (1)
- Pharmacological therapy of Alzheimer's disease (2003) (1)
- Lead-exposure associated miRNAs in humans and Alzheimer’s disease as potential biomarkers of the disease and disease processes (2022) (1)
- Biomarker counseling, disclosure of diagnosis, and follow‐up in patients with mild cognitive impairment: A European survey of EADC centers (2020) (1)
- Early detection of MCI: Is the MoCA more sensitive for cognitive decline than the MMSE (a pilot study) (2011) (1)
- EFFECT OF PRE-ANALYTICAL FACTORS ON AD BIOMARKER LEVELS IN CSF (2011) (1)
- TMEM106B the first common risk factor for FTLD: Replication in a clinically diagnosed cohort of FTLD patients (2010) (1)
- COGNITIVE FRAILTY: A NEW DOMAIN ADDED TO THE COMPREHENSIVE FRAILTY ASSESSMENT (2016) (1)
- A multigenerational family with inherited, pathologically confirmed Creutzfeldt-Jakob disease unexplained by PRNP (2009) (1)
- TDP-43 AS A BIOMARKER FOR FRONTOTEMPORAL LOBE DEGENERATION: A SYSTEMATIC REVIEW OF EXISTING ANTIBODIES (2014) (1)
- Alzheimer’s disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association (2017) (0)
- Development and analytical characterization of novel tau Simoa assays targeting full‐length tau in CSF and mid‐tau in CSF and plasma (2021) (0)
- The path to regulatory qualification of cerebrospinal fluid biomarkers as enrichment tools in clinical trials of patients with early Alzheimer’s disease: For the coalition against major diseases (2015) (0)
- VASCULAR DEMENTIA IS OVERDIAGNOSED WHEN STRUCTURAL BRAIN IMAGING IS USED IN THE CONTEXT OF STANDARD CLINICAL DIAGNOSTIC CRITERIA FOR DEMENTIA (2014) (0)
- INCREASED CSF AMYLOID-β 1-38 AND 1-40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY (2018) (0)
- Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family (2018) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease. (2023) (0)
- CHARACTERIZATION OF SUSPECTED NON-ALZHEIMER’S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING (2017) (0)
- ABCA7 PTC mutation carriers present with Alzheimer’s disease pathology and cerebral amyloid angiopathy (2020) (0)
- Genotype‐phenotype of PSEN1 p.CYS263PHE carriers in Flanders‐Belgian Alzheimer’s disease patients (2021) (0)
- Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: a BeDeCo survey (2015) (0)
- IMPROVED DIAGNOSTIC ACCURACY USING THE CEREBROSPINAL FLUID AMYLOID BETA 1-42/1-40 RATIO (2019) (0)
- Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients (2015) (0)
- Prolyl Carboxypeptidase Activity Decline Correlates with Severity and Short-Term Outcome in Acute Ischemic Stroke (2014) (0)
- Table 2. [C9orf72 Variants Discussed in This GeneReview]. (2015) (0)
- Lumbar Puncture: Consensus Guidelines (2021) (0)
- ICOBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER’S DISEASE (2019) (0)
- The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer’s disease (2015) (0)
- The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. (2012) (0)
- Genomic Characterization of the C9orf72 Repeat Region Associated with FTLD and ALS (2012) (0)
- ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER’S DISEASE (2019) (0)
- JAMA Neurology Peer Reviewers in 2017. (2018) (0)
- P1-349: Plasma amyloid isoforms allow screening for mild cognitive impairment among healthy elderly (2008) (0)
- Are depressive symptoms in mild cognitive impairment patients predictive for conversion to dementia? (2012) (0)
- Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations (2015) (0)
- APP and BACE1 miRNA genetic variability in risk for Alzheimer's disease (2009) (0)
- DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF Aβ OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2017) (0)
- P3-158 A novel locus for autosomal dominant dementia with Lewy bodies on chromosome 2Q35-36 (2006) (0)
- AMYLOID-β42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID-POSITIVE VERSUS AMYLOID-NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION (2017) (0)
- EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA (2018) (0)
- DIAGNOSTIC PERFORMANCE OF NON-PHOSPHORYLATED TAU FRACTION (PTAU REL) IN CSF AS BIOMARKER FOR DIFFERENTIAL DEMENTIA DIAGNOSIS (2016) (0)
- P4-086 5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease (2004) (0)
- Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Neuroimaging (2015) (0)
- O3-06-05: Progression of frontal lobe symptoms in frontotemporal dementia and dementia with Lewy bodies as compared with Alzheimer's disease (2008) (0)
- Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Characterisation of Depression in Dementia and Mild Cognitive Impairment (2010) (0)
- Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (2022) (0)
- Association of intermediate-length polyQ expansions in ATXN2 with ALS but not FTLD in a flanders-belgian cohort (2011) (0)
- Longitudinal stability of CSF biomarker levels (2010) (0)
- TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER’S DISEASE (2017) (0)
- PREVALENCE OF VASCULAR RISK FACTORS IN DIFFERENT STAGES OF PRODROMAL ALZHEIMER’S DISEASE AND ITS INFLUENCE ON COGNITIVE DECLINE (2016) (0)
- Mastication Dyspraxia: A Neurodevelopmental Disorder Reflecting Disruption of the Cerebellocerebral Network Involved in Planned Actions (2012) (0)
- OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE (2014) (0)
- Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis (2021) (0)
- A PROSPECTIVE NEUROGENETIC STUDY ON EARLY-ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA (2017) (0)
- THE “A/T/N” SYSTEM: ADDED PREDICTIVE VALUE OF N BIOMARKERS OF PROGRESSION FROM MCI TO DEMENTIA OVER 2 AND 4 YEARS (2017) (0)
- DISCORDANCE BETWEEN AMYLOID-PET AND CSF AMYLOID-β FOR DIAGNOSING ALZHEIMER’S DISEASE IN A CLINICAL SETTING (2016) (0)
- P4-033 Dose dependent effect of APOE ε4 on behavioral symptoms in frontal lobe dementia patients (2004) (0)
- DNA methylation differences associated with peripheral biomarkers in the EMIF‐AD cohort (2020) (0)
- PLASMA NEUROFILAMENT LIGHT CONCENTRATION PREDICTS LONG-TERM OUTCOME IN ACUTE STROKE (2016) (0)
- ICOBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER’S DISEASE (2019) (0)
- Belgian Carriers of Rare ABCA7 Mutations Present with Pronounced Cerebral Amyloid Angiopathy and Alzheimer’s Disease (2022) (0)
- Operationalizing the iwg2 and nia-aa diagnostic criteria for asymptomatic-at-risk for Alzheimer's disease or preclinical Alzheimer's disease (2015) (0)
- Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration (2018) (0)
- TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (0)
- Neutrophil gelatinase-associated lipocalin (NGAL) and its receptors in Alzheimer (AD) brain regions: differential findings in AD with and without depression (2019) (0)
- Evaluation of Cognitive Functioning Before and After Cochlear Implantation in Adults Aged 55 Years and Older at Risk for Mild Cognitive Impairment. (2023) (0)
- No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis (2017) (0)
- Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits. (2022) (0)
- Standardization of CSF sampling to minimize variation in CSF biomarker levels (2010) (0)
- High Prevalence of Hypoglycemia in People Above the Age of 75 without Diabetes Mellitus (2021) (0)
- Development and analytical performance testing of a novel sTREM2 ELISA method to support drug development (2021) (0)
- In a Large Belgian AD Cohort Loss of ABCA7 Mutations Are Associated with Alzheimer's Disease and Cerebral Amyloid Angiopathy (2020) (0)
- THE DIAGNOSTIC VALUE OF MIBG CARDIAC SCINTIGRAPHY FOR DIFFERENTIAL DEMENTIA DIAGNOSIS (2014) (0)
- P3-266: GAB2 and risk for Alzheimer's dementia in a Belgian population (2008) (0)
- Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores (2023) (0)
- MOLECULAR ANALYSIS OF TAU IN RODENT AND NON-RODENT MODELS OF AD (2014) (0)
- A family‐based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis (2020) (0)
- Plasma beta-amyloid levels: Diagnostic markers for dementia diagnosis? (2010) (0)
- PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimers disease : a BeDeCo survey Reference (2015) (0)
- RESTING STATE FUNCTIONAL MRI IN ALZHEIMER’S DISEASE: AN INNOVATIVE APPROACH FOR ROBUST EXTRACTION OF THE DEFAULT MODE NETWORK (2016) (0)
- IMPACT OF ANALYTICAL BIAS AND IMPRECISION OF CSF BIOMARKERS ON THEIR CLINICAL DIAGNOSTIC PERFORMANCE FOR AD DIAGNOSIS (2014) (0)
- The Lateralized Linguistic Cerebellum: Fact or Fallacy? (2005) (0)
- Genetic association and interaction of Alzheimer's risk genes CLU, CR1, BIN1, PICALM and MS4A in a Flanders-Belgian cohort (2012) (0)
- CONTRIBUTION OF RARE DELETERIOUS ABCA7 MUTATIONS TO A BELGIAN EARLY-ONSET ALZHEIMER’S DISEASE COHORT (2017) (0)
- MAPT p.R406W carriers present with a nonconforming FTD phenotype in the Belgian Flemish population (2020) (0)
- QUANTIFICATION OF CSF Aβ1-38, TOGETHER WITH APOLIPOPROTEINS E, CAN IMPROVE THE CLINICAL DIAGNOSTIC ACCURACY FOR AD OF THE CSF TAU AND Aβ ASSAYS (2014) (0)
- P4-176 Actigraphic measurement of agitated behavior in dementia (2006) (0)
- Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study (2020) (0)
- The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer’s disease (2015) (0)
- Otolith vestibular function appears to affect human hippocampal volume (2023) (0)
- Genomic characterization of the C9orf72 promoter repeat in FTLD and ALS patients (2012) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- FDG-PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER’S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS (2017) (0)
- ABCA7 mutations are major contributors to Alzheimer’s disease in Belgian patients (2020) (0)
- Experiences with and perspectives on advance care planning in young- and late- onset dementia: A focus group study with physicians from various disciplines (2023) (0)
- JAMA Neurology Peer Reviewers in 2017. (2018) (0)
- The CSF Aβ1-40/Aβ1-42 ratio for differential dementia diagnosis (2011) (0)
- ANALYSIS OF SQSTM1 IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE (2014) (0)
- Diagnostic performance of automated MRI volumetry by icobrain DM for Alzheimer's disease in a clinical setting: A REMEMBER study (2021) (0)
- A new era of CSF biomarker testing in the field of Alzheimer's disease (2013) (0)
- CSF EXPLORATORY BIOMARKER STUDY FOR (DIFFERENTIAL) DIAGNOSIS OF FRONTOTEMPORAL LOBAR DEGENERATION (2016) (0)
- Alzheimer's disease and cerebral amyloid angiopathy were associated with ABCA7 PTC mutation carriers in a large Belgian AD cohort (2020) (0)
- PERFORMANCE EVALUATION OF AUTOMATIC BRAIN MRI SUBSTRUCTURE SEGMENTATION WITH ICOBRAIN (2018) (0)
- Improved Alzheimer’s Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study (2019) (0)
- CLINICAL RELEVANCE OF APOE GENOTYPING AND APOLIPOPROTEIN E-ɛ4 IMMUNOASSAYS IN ALZHEIMER'S DISEASE (2014) (0)
- Uptake of AV-1451 was assessed by visual read and by regional analysis with intensity standardization to cerebellar grey matter (2019) (0)
- COMT and DRD3 polymorphisms are associated with agitated behaviour and frontal lobe symptoms in dementia (2007) (0)
- P3-352 The middelheim frontality score: a behavioral assessment scale that discriminates frontotemporal dementia from Alzheimer's disease (2004) (0)
- P3‐408: WITHDRAWN (2018) (0)
- Cerebrospinal fluid amyloid status and affective symptoms in mild cognitive impairment (2020) (0)
- O3-01-06 Diagnostic performance of a CSF-biomarker panel compared to clinical diagnosis in 100 autopsy-confirmed dementia cases (2006) (0)
- Rare missense mutations and compound heterozygous mutations in ABCA7 contribute to Alzheimer's disease in Belgian patients (2021) (0)
- Electrochemical Skin Conductance Alterations during Spinal Cord Stimulation: An Experimental Study (2021) (0)
- DT‐01‐06: Withdrwan (2015) (0)
- ABCA7‐reducing mutation carriers have reduced CSF amyloid biomarker levels, suggestive of increased amyloid deposition (2022) (0)
- P2-191: Neuropathological and biochemical characterization of GRN mutation carriers and GRN conditional mice (2008) (0)
- P3-206: Genetic variability at the progranulin locus contributes to risk for Alzheimer's disease (2008) (0)
- SCREENING AND RECRUITMENT EXPERIENCE WHEN USING BIOMARKER-BASED POPULATION DEFINITION IN ALZHEIMER’S DISEASE STUDIES (2016) (0)
- Accelerated Cognitive Decline Associated With Hearing Loss and Bilateral Vestibulopathy: Insights From a Prospective Cross-Sectional Study Using the Repeatable Battery for the Assessment of Neuropsychological Status Adjusted for the Hearing Impaired in the DFNA9 Population. (2022) (0)
- In‐depth phenotypic description of pathogenic TBK1 mutations: A frequent cause of FTD and ALS in the Flanders‐Belgian population (2021) (0)
- Inter‐ and intra‐scanner variability of icobrain DM automated brain volumetry software on three different MRI systems (2021) (0)
- DELETERIOUS ABCA7 MUTATIONS CONTRIBUTE TO EARLY-ONSET ALZHEIMER’S DISEASE AND ARE SUBJECT TO TRANSCRIPT RESCUE MECHANISMS (2017) (0)
- Targeted re-sequencing of sorl1 in early-onset Alzheimer’s dementia: The european early onset dementia consortium (2015) (0)
- Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer’s disease (2015) (0)
- NPTX2 LEVELS IN CSF AS POTENTIAL PREDICTOR OF COGNITIVE DYSFUNCTION IN THE AD CONTINUUM (2019) (0)
- In-depth molecular genetic analysis of CLU in Alzheimer's disease (2010) (0)
- Prognostic value of frontal lobe symptoms in mild cognitive impairment for conversion to Alzheimer's disease (2011) (0)
- Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
- PRE-SCREENING FOR EPISODIC MEMORY DEFICITS CAN ENRICH FOR ELIGIBLE SUBJECTS IN EARLY ALZHEIMER’S DISEASE CLINICAL TRIALS (2017) (0)
- PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER’S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT (2018) (0)
- Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors (2016) (0)
- INVESTIGATING THE INVOLVEMENT OF THE DPP6-KV4.2 PROTEIN COMPLEX IN DEMENTIA (2019) (0)
- A novel assay for the quantification of M-Tau in cerebrospinal fluid (2013) (0)
- DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER\textquotesingleS DISEASE PATHOLOGY AND PROGRESSION (2017) (0)
- INCREASED CSF LEVELS OF BIOMARKERS FOR NEURODEGENERATION IN FTLD-GRN MUTATION CARRIERS (2016) (0)
- Recommendations to standardize Pre-analytical confounding factors in Alzheimer ’ s and Parkinson ’ s disease CSF biomarkers : an update (2015) (0)
- Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment (2020) (0)
- Microtubule associated protein tau p.R406W patient carriers present with a nonconforming clinical phenotype (2022) (0)
- P3-037 CSF dopac levels predict aggressive and agitated behavior in FTD patients (2004) (0)
- Diagnostic Evaluation of Dementia (2021) (0)
- Sex-specific metabolic pathways associate with Alzheimer's Disease (AD) endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery (EMIF-AD MBD) cohort (2021) (0)
- Investigating Tissue-Specific Abnormalities in Alzheimer’s Disease with Multi-Shell Diffusion MRI (2022) (0)
- Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study (2018) (0)
- 72 G 4 C 2 repeat expansions in Alzheimer ’ s disease and mild cognitive impairment (2013) (0)
- Genetic contribution of PGRN, MAPT, VCP, and CHMP2B to the etiology of frontotemporal dementia (2007) (0)
- P2-142 Diagnostic performance of a CSF-biomarker panel in 100 autopsy-confirmed dementia cases as analyzed with single and multiparameter tests (2006) (0)
- IMPACT OF BIOMARKERS ON DIAGNOSTIC CONFIDENCE IN CLINICAL ASSESSMENT OF PATIENTS WITH SUSPECTED ALZHEIMER'S DISEASE AND HIGH DIAGNOSTIC UNCERTAINTY: AN EADC STUDY (2016) (0)
- Meta-Analysis of Rare CLU Variants Shows Association With Alzheimer's Risk and Calls Attention To The CLU Beta-Subunit (2011) (0)
- Clinical indications for analysis of Alzheimer's (2013) (0)
- Diagnostic value of CSF biomarkers for (differential) dementia diagnosis (2011) (0)
- The practice of dementia care: Belgium (2005) (0)
- Correlates of cerebrospinal fluid neurotransmitter alterations with behavioral disturbances in dementia (2011) (0)
- The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics (2018) (0)
- MONOAMINERGIC NEUROTRANSMITTER LEVELS IN POST-MORTEM BRAIN REGIONS OF PATIENTS WITH LEWY BODY AND ALZHEIMER'S DEMENTIA: ASSOCIATION WITH DEPRESSION AND PSYCHOSIS (2014) (0)
- Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap (2021) (0)
- F1â•’01â•’04: DEMENTIA WITH LEWY BODIES (2018) (0)
- Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains (2015) (0)
- Extensive genetic and phenotypic description of MAPT p.R406W in the Flanders‐Belgian population (2021) (0)
- The clinical presentation of C9orf72-associated frontotemporal lobar degeneration in an extended Flanders-Belgian cohort (2012) (0)
- Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study (2019) (0)
- Adults with cerebral palsy and Alzheimer disease: a missing link? (2021) (0)
- Identification of plasma proteome signatures associated with ATN framework using SOMAscan (2020) (0)
- Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson’s disease (2021) (0)
- Exploring the Cost of ‘Ageing in Place’: Expenditures of Community-Dwelling Older Adults in Belgium (2018) (0)
- Alzheimer’s disease CSF biomarkers: clinical indications and rational use (2017) (0)
- Follow up of Alzheimer's disease with psychosis genome-wide association studies (2012) (0)
- BEHAVIORAL SYMPTOMS ASSOCIATED WITH PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY (2014) (0)
- Dementia : diagnosis, behaviour management, ethical issues (2016) (0)
- MONOAMINERGIC BRAIN TOPOCHEMISTRY IN ALZHEIMER'S DISEASE VERSUS HEALTHY ELDERLY (2014) (0)
- Recessive missense variants in VWA2 increase risk of developing Alzheimer’s disease (2020) (0)
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation (2018) (0)
- Anti-CASPR2 antibody-associated limbic encephalitis in a patient with a squamous cell carcinoma of the throat (2023) (0)
- P3-149 An ancestral haplotype harbors a highly prevalent mutation for 17q21-linked tau-negative FTLD in Belgium (2006) (0)
- Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example (2015) (0)
- Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update (2012) (0)
- Repetitions in the connected speech of a patient with semantic dementia (2013) (0)
- COGNITIVE FRAILTY AND ITS RELATION WITH PHYSICAL, PSYCHOLOGICAL, SOCIAL AND ENVIRONMENTAL FRAILTY (2017) (0)
- CSF BIOMARKERS TO PREDICT RATE OF COGNITIVE DECLINE IN ALZHEIMER’S DISEASE (2016) (0)
- Promoter DNA methylation regulates progranulin expression and is altered in FTLD (2013) (0)
- DIFFUSION KURTOSIS IMAGING: A BIOMARKER FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE? (2014) (0)
- ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT-LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS (2019) (0)
- Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity (2016) (0)
- BRIEF NEUROPSYCHOLOGICAL SCREENING TESTS FOR THE DETECTION OF ALZHEIMER’S DISEASE IN AN EARLY PHASE: A SYSTEMATIC REVIEW (2016) (0)
- munoassays for the clinical diagnostic work-up of AD. P4-069 DEVELOPMENT OFA PROCESS TO DISCLOSE AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL OLDER ADULT RESEARCH PARTICIPANTS (2014) (0)
- IN-DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER’S DISEASE (2018) (0)
- Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum (2022) (0)
- P3-080: Value of CSF biomarkers in differential dementia diagnosis (2008) (0)
- RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT-LIGHT AND YKL-40 TO Aβ, APOE ε4 AND COGNITION: RESULTS FROM THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY (2018) (0)
- BLOOD FLOW–INDEPENDENT QUANTIFICATION OF [18F]-AV45 PET USING MODEL-BASED KINETICS WITH A METABOLITE-CORRECTED ARTERIAL INPUT FUNCTION (2016) (0)
- P1-052 A prospective, longitudinal Belgian study on behavioral and psychological signs and symptoms of dementia (2004) (0)
- Homozygous and compound heterozygous rare variants in VPS13C contribute to Lewy body diseases (2020) (0)
- JAMA Paper supplement (2015) (0)
- Clinical Evidence for Disease Anticipation in Families Segregating a C9orf72 Repeat Expansion (S21.006) (2016) (0)
- Cerebrospinal fluid tau levels indicate aberrant neuronal plasticity in Alzheimer disease (2020) (0)
- Acute ischemic stroke severity , progression and outcome relates to changes in dipeptidyl peptidase IV and fibroblast activation protein activity Reference (2016) (0)
- MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF-AD BIOMARKER DISCOVERY STUDY (2018) (0)
- PSP and small vessel disease: more than occasional co-occurence? (2016) (0)
- [Searched for and found: non-demented patients with Alzheimer's disease]. (2011) (0)
- PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sebastiaan Engelborghs?
Sebastiaan Engelborghs is affiliated with the following schools:
